Kevin De Braganca is the Head, CAR-T, for the US Oncology Medical Affairs team. Kevin has extensive experience with CAR-T therapy encompassing patient and physician needs, clinical management, manufacturing issues and transportation logistics. He joined Janssen R&D in 2018 as the Study Responsible Physician the Phase 2 Cilta-cel study, CARTITUDE-2.

Prior to joining Janssen Pharmaceuticals, Kevin was an Assistant Attending Neuro-Oncologist in the Departments of Pediatrics and Neurology at Memorial Sloan Kettering Cancer Center. He treated children and adults with primary brain tumors. Kevin also cared for patients experiencing neurotoxicity due to cancer and treatment side effects (including CAR-T therapy).

Kevin received his MD from UMDNJ (Rutgers), Newark. He completed his residency in Pediatrics at Columbia University and a fellowship in Child Neurology at Children’s National Medical Center. He completed a second fellowship in Adult Neuro-Oncology at Memorial Sloan Kettering and was chief fellow. He has been board certified in Pediatrics, Neurology with Special Qualification in Child Neurology and Neuro-Oncology.